Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Got them all back for $0.83 four parts this time.
1.19 to 0.83 = 30% in less then one month.
Break-Even Price 1.5624 now showing.
Sliced again at $1.19 went through in 7 parts final 67 went through at $1.195
Bep still 2.0591.
Only have the 13/3/24 Buy of $1.06 left of the post 7/8/23 1for10 Consolidation left.
Not sure how much I am down here.
Analysts expect the price to increase by 655%.
Sold again at $0.94 went through in 11 parts , but within the minute . 7.38pm wile in the pool.
This the buy 15/4/24 at $0.87 .
1,387 for 1,499 = £112 = 8% over 16days
2 recent buys after the consolation left , have to think before selling those.
Bep 2.0591 and showing only loss.
Second sale today for $0.86 five part from 6.32pm to 6.42pm.
This the buy on 18/4/24 for $0.805.
0.805 to 0.86 = 7% approx.
The buy a 46% deal size .
Not quite as much money gain as the first today .
The 4 Analysts still expect the price to increase $6.667
Break-Even Price 2.0591
Sold last buy back saw 5 % up traveling home at 3.30pm .
Set as last weeks $0.81 target strait through $0.8205 .
Topping out 0.846 just after my sale.
Placed a further order to sell .
0.75 to 0.8205 = 9.4% exactly .
The buy only 42.8 % deal size , made a couple of pounds more then the 9.4% in cash terms .
Ex rate must have improved .
Fx 1.237 for the buy on 19th
Fx 1.2529 for today's sell.
Bought more today at $0.75 x 718.
Under the pre consolidation now.
Hope it is not going bust .
Spare cash and addicted to dealing .
Plenty of news this the latest
RNS 17/4/24
Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
Bought more today at $0.805 x 718.
4 Analysts expect the price to increase by 717% to $6.667 did not note the $ target 14th March below.
Four buys now after the consolidation was buying this time last year 10 times higher.
It has nearly gone below the pre 7/8/23 Consolidation 1for10 ** price
20/4/23 buy $0.77 x 524 ** ( eqv $7 ) one day after and paid more.
19/4/23 big fall to 0.64 -13% ( eqv $6.7 )
Bought more today at $0.87 x 718.
718 Shares bought today .
700 last time 13/3/24 ( order had been 718 )
All time low of $1
Bought more today at $1 x 518. ( must be equal to $0.1 pre Consolidation )
Fx 1.2542
Appears 9th August 2023 I could not buy for $4
7th August 23 was the Consolidation 1for10 **
The sell below on 5th August 2022 for $2.41 x 524 , must be equal to $24.1 x 52 shares.
4 Analysts expect the price to increase by 529%.
Plenty of fund managers.
13/3/24 Buy $1.06 x 500 new low.
9/8/23 order on $4 x 359 ( Buy ? ) thank God that failed.
7/8/23 Consol 1for10 **
21/4/23 Order failed to execute 0.6 x 524 ( eqv $6.77 ) Thank God with 14/3/24 hindsight .
20/4/23 buy $0.77 x 524 ** ( eqv $7 ) one day after and paid more.
19/4/23 big fall to 0.64 -13% ( eqv $6.7 )
18/4/23 buy $0.8 ( closed 0.7503 eqv $6.79 )
24/2/23 buy $1.28
21/2/23 buy 1.39
05/8/22 sell $2.41 x 524 eqv $24.1 x 52 shares.
01/6/22 buy 1.6
27/5/22 sell 1.75 21/4/23 failed 0.6x524
09/5/22 buy 1.39
17/2/22 buy 2.05
09/2/22 sell 2.42
31/1/22 sell 2.16
24/1/22 buy 1.87
21/1/22 buy 2.21
13/1/22 buy 2.59
Bought more today for $0.8 fx 1.2427
No need to up it from $0.79 closed $0.75
18% drop today a low of $0.79
The Motley Fool April 11th 2023
3 Supercharged Growth Stocks With 662% to 741% Upside, According to Wall Street.
Bionano Genomics: Implied upside of 662%
You don't need a mega-cap stock to get a sky-high price target. Small-cap genome analysis company Bionano Genomics (NASDAQ: BNGO) proves this.
In January, Ladenburg Thalmann analyst Jeffrey Cohen reiterated his and his firm's $8 price target on Bionano after the company announced its preliminary fourth-quarter operating results. According to Cohen, additional clinical data should support the company's commercialization and reimbursement efforts for optical genome mapping (OGM) system Saphyr. If Cohen's price target proves accurate, shareholders as of the end of last week would enjoy an eventual gain of 662%.
Bionano's Saphyr system is designed to detect structural genome variations. The idea here is that researchers, such as drug developers and universities, can utilize Saphyr to detect structural variations in hard/difficult-to treat diseases. In doing so, new approaches can be attempted by drugmakers to cure these diseases, or at the very least improve patient care. Bionano Genomics has released a laundry list of case studies where Saphyr has successfully identified genome variations for a number of hard-to-treat diseases and ailments.
Why hasn't Bionano Genomics rocketed to the moon if Saphyr is such a superstar? The simple answer is that Saphyr isn't approved by the U.S. Food and Drug Administration (FDA), and there's no precise timeline as to if or when that'll happen. Without this approval, placing Saphyr systems and getting reimbursed has been dicey.
The other concern for the rapidly growing Bionano Genomics is funding the company's growth. It closed out 2022 with $113.2 million in cash, cash equivalents, and available securities for sale. However, just a day after releasing its full-year results, the company filed a $400 million mixed-shelf offering that would give it more flexibility to raise cash. While this doesn't guarantee Bionano will raise additional capital, it's a pretty good indication that existing shareholders could be diluted, in some capacity, if operating losses continue.
Although Bionano Genomics is a company with intriguing technology, its operating losses would have to shrink considerably if its stock is to make a run at $8.
Bought more today for $1.28 Fx 1.1911.
The Fx rate much worse the three days ago at fx 1.2073
Bought that tranche back today for $1.39 again two parts but same time .
4th USA buy on tech 100, 2% day fall back fx 1.2073
2.44 to 1.39 = 43 % ( 5th August 2022 sale )
From below most other buys all look higher then today's $1.39 , "I see a cheaper by on 9th May 2022 @ $1.38 "
Trouble finding this one , actually has its own page on here ,
Slice sale went through yesterday night Friday 5th August 2022 at *$2.44 in two parts a smaller one at 8.48pm all remainder 8.57pm :-)
After that partial sale on 27th May posted below ( no mention of more recent trades )
I bought a *full size tranche size back for $1.6 on 1st June 2022.
So I have 3 tranches left , the first bought at $2.59 on 13/1/22 almost in profit , the second at 2.2 is in profit .
The third at $1.87 is now well up .
The last buy cheaper then all but one before, I see a cheaper by on 9th May 2022 @ $1.38 that was only partially sold back on 27th May 22 for $1.75.... hence the last full buy back cheaper then the partial sale on 1st June 2022.
Thank God now the sale was partial .
This little one has its own page on LSE .
A partial sale lifted yesterday Friday 27th for $ 1.75 just before close at 8.54pm .
The live price feed irreverent this time as order was on a few hours must be volatile, as I set well above days high just two hours before at 7pm .
About 10% of a deal .
Topped up yesterday did not notice price feed was live* and it was lower then days low at moment I placed deal so flew strait threw at $1.39 first batch then 2 parts at 1.38 . First buy in USA tumbling markets 4.22pm .
The 3 parts less then the 10 last time .
But yesterday day Mereo went through in 18 parts .
This showing no change in price today .
This was the first buy of very busy day 11 USA buys ( placed 33 orders )
Bought that sold tranche back for $2.05 , went through in 10 parts .
always the order executes in bits ( 2 and 7 before )
Just original buy left now .
Why is no one talking about these shares?
Why is no one talking about this ?!
Nice rise. Even those in on open have benefitted.